A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study

ConclusionsIn the MOBILITY3 study (NCT02506517), afatinib demonstrated modest activity in tumors that possessEGFR andERBB2 aberrations. Clinical benefit seen in all 3 salivary gland cancers supports the growing evidence for the utility of HER-targeted therapies in the treatment of this specific tumor type.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research